# Patient Registry Software Market

> Patient Registry Software Market Research Report By Solution Type (Standalone Software, Integrated Software, Cloud-Based Software, Web-Based Software), By Application (Chronic Disease Registries, Rare Disease Registries, Patient-Reported Outcomes Registries, Clinical Trial Registries), By Deployment Type (On-Premise, Cloud), By End User (Hospitals, Research Organizations, Healthcare Providers, Government Agencies) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 13.2%
- **2025:** USD 2.06 Billion
- **2035:** USD 7.01 Billion
- **Key Players:** IQVIA Holdings, Oracle Health, Optum, Merative, ArborMetrix, Q-Centrix, Dacima Software, ImageTrend

**Report ID:** MRFR/HC/5452-CR · **Pages:** 200 · **Author:** Rahul Gotadki & Nidhi Mandole · **Last Updated:** September 11, 2026

**URL:** https://www.marketresearchfuture.com/reports/patient-registry-software-market-6917

---

## Market Summary

## Patient Registry Software Market Summary

The Patient Registry Software Market was valued at USD 2.06 billion in 2025 and is set to open the forecast window at USD 2.30 billion in 2026 before reaching USD 7.01 billion by 2035, expanding at a 13.2% CAGR. Two catalysts explain most of that trajectory. The first is the U.S. ONC HTI-1 rule, which made standardized FHIR APIs a condition of health IT certification [[1]](https://healthit.gov). The second is the European Health Data Space regulation, which obliges member states to build federated secondary-use infrastructure by 2029 [[2]](https://health.ec.europa.eu).

Legacy architecture is what is actually being displaced here. Spreadsheet-based abstraction, single-site Access databases, and bolt-on modules inside older EHR suites are giving way to cloud-native platforms with OMOP common data model support and automated quality checks. The NIH allocated roughly USD 291 million to real-world data infrastructure across its 2024–2025 cycles, and sponsors report that AI-assisted chart abstraction trims curation labour by close to 40% [[3]](https://nih.gov)[[4]](https://academic.oup.com).

Regionally, North America commands 47.3% of 2025 revenue, anchored by CMS quality-reporting mandates. Asia-Pacific grows fastest at a 14.6% CAGR as India and China scale national disease surveillance. Europe ranks second on the strength of EHDS-driven procurement. Buyers now shortlist on interoperability, not features.

## Key Report Takeaways

### • By Software Solution

- Cloud-deployed SaaS platforms held 57.9% of 2025 revenue in the Patient Registry Software Market, the largest single technology block.
- Integrated EHR-embedded registries generated USD 0.52 billion in 2025
- Stand-alone deployments are decelerating to an 8.4% CAGR through 2035

### • By End User

- Hospitals and health systems accounted for 44.2% of 2025 revenue
- Research institutes and academic medical centres are the fastest-expanding buyer group at a 16.8% CAGR
- Government agencies and third-party administrators contributed USD 0.44 billion in 2025

### • By Region

- North America led the Patient Registry Software Market with 47.3% of 2025 revenue.
- Asia-Pacific is forecast to compound at 14.6% through 2035
- Europe delivered USD 0.55 billion in 2025 revenue

## Market Size and Forecast (2021–2035)

Estimates below blend bottom-up vendor revenue triangulation, health-system procurement disclosures, and grant-award data from public funders, reconciled against a top-down view of registry-eligible clinical sites. Historical years reflect audited or reported vendor figures; forecast years apply the calibrated 13.2% CAGR for the Patient Registry Software Market.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Interoperability and FHIR mandates | 24 | North America, Europe | Short-term (≤2 yr) | [1] |
| Regulator demand for real-world evidence | 21 | Global | Medium-term (2–4 yr) | [9] |
| Cloud and SaaS cost economics | 18 | Global | Short-term (≤2 yr) |   |
| AI-assisted data abstraction | 15 | North America, Europe | Medium-term (2–4 yr) | [4] |
| Value-based care quality reporting | 12 | North America | Medium-term (2–4 yr) | [8] |
| National health data programmes | 11 | Asia-Pacific, MEA | Long-term (≥4 yr) | [7] |
| Precision-medicine cohort funding | 9 | Global | Long-term (≥4 yr) | [3] |

### Interoperability Mandates Are Rewriting Procurement Criteria

These days, certification regulations determine which companies make the short list. Standardized FHIR endpoints must be exposed by certified health IT in order to comply with HTI-1, and non-compliant devices lose their ONC accreditation completely [[1]](https://healthit.gov). In response, hospitals retired custom connectors; in 2025, almost 68% of U.S. health systems reported having active FHIR-based registry feeds, up from 34% two years prior. Spending in the Patient Registry Software Market shifted from integration consulting to platform licenses as a result of this change.

### Real-World Evidence Has a Regulatory Home

Agencies now accept registration data, so sponsors submit it. Since 2019, over 90 label expansions and post-approval commitments have been supported by the FDA's real-world evidence framework, and registries are required by EU MDR Article 83 to provide post-market clinical follow-up at a fraction of trial costs [[9]](https://fda.gov). The average annual cost of a single device registry is between USD 1.2 and 2.5 million, while a comparable prospective research would cost more than USD 18 million.

### Cloud Economics Removed the Capital Barrier

Deployment cost, not clinical need, historically gated registry adoption. Cloud subscriptions cut first-year outlay by an estimated 55–60% against on-premise builds and eliminate upgrade projects entirely. Mid-sized community hospitals — previously priced out — now represent the fastest-growing buyer cohort by unit count.

### AI Abstraction Attacks the Largest Cost Line

Manual chart abstraction absorbs 60–70% of registry operating budgets. Large-language-model extraction pipelines validated at several academic centres reduced abstractor hours by approximately 40% while holding concordance above 94% [[4]](https://academic.oup.com). Vendors that bundle abstraction credits into subscription pricing are winning multi-year renewals.

## Restraints

## Restraints Impact Analysis

Restraint weightings are directional analyst estimates of drag on growth momentum. They quantify friction intensity rather than a subtractable percentage of the compound rate.

| Restraint | ~% Drag on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Fragmented data privacy regimes | 26 | Europe, Asia-Pacific | Long-term (≥4 yr) | [2] |
| Clinician documentation burden | 22 | Global | Medium-term (2–4 yr) | [10] |
| Legacy EHR migration complexity | 19 | North America | Medium-term (2–4 yr) | [11] |
| Sustained funding uncertainty | 17 | Global | Short-term (≤2 yr) | [3] |
| Data quality and completeness gaps | 14 | Emerging markets | Long-term (≥4 yr) | [7] |

### Privacy Fragmentation Slows Cross-Border Cohorts

Secondary use is only permitted under member-state derogations under GDPR Article 9, and these derogations vary greatly; Germany's research clause differs significantly from France's CNIL reference procedures [[2]](https://health.ec.europa.eu). As a result, multinational sponsors operate multiple national instances rather than a single cohort, increasing deployment costs by an estimated 30 to 45 percent.

### Documentation Burden Caps Clinician Participation

For every hour of direct care, doctors currently devote about 1.8 hours to documentation [[10]](https://acpjournals.org). Within eighteen months, desertion rates exceed 40% for registries that require discrete fields outside the regular process. Although vendors are responding with passive capture, human approval is still needed for validation.

### Migration Debt Delays Replacement Cycles

Health systems carry decades of unstructured registry history. Mapping legacy schemas to OMOP typically consumes nine to fourteen months and USD 400,000–900,000 before a single new record is captured [[11]](https://himss.org), which pushes replacement decisions past budget cycles.

## Opportunities

## Patient Registry Software Market Opportunities

### Federated Query Networks

Analysis-to-data methods are becoming more and more preferred by regulators over data pooling. EHDS-compliant demand can be met by platforms that provide federated execution among sovereign nodes without causing transfer constraints. Multi-country framework agreements for USD 8–20 million are being signed by early adopters.

### Pregnancy and Maternal-Child Surveillance

The FDA's TEMPO pilot lowered obstetric device surveillance cost and created a template other therapeutic areas will copy [[9]](https://fda.gov). This segment is the fastest-growing registry type, and vendors with validated maternal outcome modules face limited competition.

### Emerging-Market National Programmes

National registry layers are funded by Saudi Arabia's Health Sector Transformation Program and India's Ayushman Bharat Digital Mission, with a total commitment to digital health spending reaching USD 4.5 billion through 2030 [[7]](https://who.int). Here, low-bandwidth speed and localization are more important than feature depth.

### Data Monetization and Evidence-as-a-Service

De-identified registry cohorts command genuine licensing value. Academic consortia now realize USD 250,000–1.5 million per sponsor study through governed data access, and the Patient Registry Software Market is shifting toward revenue-share models where vendors take a cut of downstream evidence contracts.

### Payer-Provider Convergence

Value-based contracts require shared outcome truth. Registries that serve both quality attestation and actuarial risk adjustment consolidate two budget lines into one platform purchase [[8]](https://cms.gov).

## Future Outlook

## Patient Registry Software Market Future Outlook

### Autonomous Curation Becomes the Default

By 2030, most abstraction work in the Patient Registry Software Market will run unattended, with humans reviewing exceptions only. Concordance benchmarks above 95% are already achievable on structured oncology staging [[4]](https://academic.oup.com), and once payers accept machine-curated submissions, the cost floor for registry participation collapses.

### Platform Economics Favour Consolidation

Registry buyers increasingly want one contract covering capture, governance, analytics, and submission. Point solutions face margin compression as suites bundle capabilities, and the top-tier vendors are acquiring specialty modules rather than building them.

### Evidence Markets Mature

Governed data access is becoming a product line. OECD analysis suggests health data reuse could deliver system savings equivalent to 1–2% of health expenditure in advanced economies [[13]](https://oecd.org), and registry operators are positioning to capture part of that value through licensing.

### Sovereignty Reshapes Architecture

Data-residency rules in the EU, India, and the Gulf are pushing vendors toward multi-region deployments with local key management. Firms that cannot demonstrate sovereign hosting will be excluded from public tenders, a structural filter that will define competitive ranking in the Patient Registry Software Market well into the 2030s.

## Segment Insights

## Patient Registry Software Market Segmentation

Segmentation in the Patient Registry Software Market mirrors how registries are purchased: by clinical purpose, by delivery model, and by institutional buyer.

### By Type of Registry

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Disease Registries | 45.2% share | Chronic condition outcome tracking |
| Health Service Registries | USD 0.44 Billion | Quality and safety reporting |
| Product Registries | USD 0.36 Billion | Device post-market surveillance |
| Pregnancy & Maternal-Child Registries | 15.7% CAGR | Obstetric safety surveillance |
| Other Registries | 6.8% share | Rare disease and genomics cohorts |

Disease registries dominate the Patient Registry Software Market because oncology, cardiology, and rheumatology societies have institutionalized them over two decades. Pregnancy and maternal-child registries grow fastest from a small base, propelled by the TEMPO pilot's demonstration that obstetric device surveillance can be run at materially lower cost [[9]](https://fda.gov).

### By Software Solution

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Cloud-Deployed SaaS | 57.9% share | Low capital outlay, automatic upgrades |
| Integrated EHR-Embedded | USD 0.52 Billion | Workflow-native capture |
| Stand-Alone | 8.4% CAGR | Specialty society independence |

Cloud SaaS leads the Patient Registry Software Market on economics alone, and its lead widens as FHIR compliance becomes a vendor-managed obligation rather than a customer project. EHR-embedded registries hold their ground where documentation burden is the binding constraint, since capture happens inside the clinician's existing workflow.

### By End User

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Hospitals & Health Systems | 44.2% share | Accreditation and quality mandates |
| Government & Third-Party Administrators | USD 0.44 Billion | Population health surveillance |
| Pharmaceutical & Medical Device Companies | 18.6% share | Post-approval evidence obligations |
| Research Institutes & Academic Medical Centres | 16.8% CAGR | Precision-medicine grant funding |

Hospitals anchor the Patient Registry Software Market through unavoidable accreditation reporting. Academic centres grow fastest because grant conditions increasingly require durable, shareable cohort infrastructure rather than project-scoped databases [[3]](https://nih.gov).

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 47.3% share | Quality reporting, device surveillance |
| Europe | USD 0.55 Billion | EHDS compliance, federated networks |
| Asia-Pacific | 14.6% CAGR | National digital health missions |
| South America | 4.1% share | Oncology and rare disease cohorts |
| Middle East & Africa | USD 0.07 Billion | Sovereign health transformation |
| Total | USD 2.06 Billion | — |

Regional demand in the Patient Registry Software Market tracks regulatory maturity far more closely than healthcare spending alone.

### North America

| Country | Metric | Key Driver |
| --- | --- | --- |
| US | 84.5% of region | CMS MIPS and QCDR reporting |
| Canada | USD 0.09 Billion | Provincial cancer registry renewal |
| Mexico | 14.1% CAGR | IMSS digitization programme |

CMS qualified clinical data registry rules give U.S. specialty societies a direct financial reason to maintain platforms, and more than 60 QCDRs were approved for the 2025 performance year [[8]](https://cms.gov). North America's share of the Patient Registry Software Market therefore rests on recurring compliance spend rather than discretionary innovation budgets, which makes it unusually recession-resistant.

### Europe

| Country | Metric | Key Driver |
| --- | --- | --- |
| Germany | 23.4% of region | Medical Informatics Initiative |
| UK | USD 0.11 Billion | NHS Secure Data Environments |
| France | 14.2% of region | Health Data Hub projects |
| Italy | 12.6% CAGR | Regional oncology networks |
| Spain | 7.8% of region | Rare disease registry consolidation |
| Nordic Countries | USD 0.05 Billion | Population-linkage infrastructure |
| Russia | 3.9% of region | State oncology programme |
| Rest of Europe | 11.4% CAGR | EHDS readiness spending |

Germany's Medical Informatics Initiative committed over EUR 500 million across university-hospital data integration centres, creating the continent's densest cluster of OMOP-mapped clinical patient data registries [[2]](https://health.ec.europa.eu). The UK's Secure Data Environment policy pushed procurement toward trusted research environments with embedded governance tooling.

### Asia-Pacific

| Country | Metric | Key Driver |
| --- | --- | --- |
| China | 29.6% of region | National tumour registry expansion |
| India | 17.2% CAGR | Ayushman Bharat Digital Mission |
| Japan | USD 0.08 Billion | MID-NET post-marketing surveillance |
| South Korea | 9.4% of region | K-CURE cancer data platform |
| ASEAN | 15.8% CAGR | Universal coverage digitization |
| Rest of Asia-Pacific | 6.7% of region | Academic cohort funding |

Asia-Pacific is the growth engine of the Patient Registry Software Market because national programmes, not individual hospitals, do the buying. India registered more than 400 million ABHA health accounts by 2025, generating a linkage substrate that registries can query directly [[7]](https://who.int). Japan's MID-NET remains the region's most mature pharmacovigilance-linked deployment.

### South America

| Country | Metric | Key Driver |
| --- | --- | --- |
| Brazil | 54.8% of region | SUS oncology data modernization |
| Argentina | USD 0.02 Billion | Public hospital digitization |
| Rest of South America | 12.9% CAGR | Donor-funded disease surveillance |

Brazil's Ministry of Health has been consolidating fragmented state cancer registries into a unified national instance, a project sized in the tens of millions of dollars and dependent on low-cost cloud hosting [[12]](https://gov.br/saude). Currency volatility remains the main constraint on multi-year licensing.

### Middle East & Africa

| Country | Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 28.3% of region | Vision 2030 health transformation |
| UAE | 16.4% CAGR | Malaffi and Riayati exchanges |
| South Africa | USD 0.01 Billion | HIV and TB cohort reporting |
| Egypt | 11.2% of region | Hepatitis C elimination follow-up |
| Rest of MEA | 25.9% of region | Donor and NGO programmes |

Saudi Arabia's Health Sector Transformation Programme has funded sovereign cloud health platforms with explicit registry components, and the UAE's Malaffi exchange now covers the overwhelming majority of Abu Dhabi encounters [[7]](https://who.int). Vendors that meet data-residency requirements win disproportionately here.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration is moderate. The estimated HHI sits near 780, with the top five vendors holding roughly 40–46% of global revenue in the Patient Registry Software Market. The remainder is split among specialty-society platforms and regional providers, which keeps the field fragmented at the mid-tier while consolidating at the top.

| Company | Est. Revenue Share Range | Key Offerings for Patient Registry Software Market | Strategic Positioning |
| --- | --- | --- | --- |
| IQVIA Holdings | ~11–14% | Registry platforms, RWE analytics | Scale leader in sponsor-funded registries |
| Oracle Health | ~8–11% | EHR-embedded registry modules | Bundles registry with core EHR estate |
| Optum | ~7–9% | Population analytics, quality reporting | Payer-provider convergence play |
| Merative | ~5–8% | Clinical data repositories, cohort tools | Life-sciences evidence focus |
| ArborMetrix | ~4–6% | Specialty society registry platforms | Deep QCDR and benchmarking expertise |
| Q-Centrix | ~4–6% | Managed abstraction and registry services | Services-led, outcome-guaranteed model |
| Dacima Software | ~3–5% | Configurable EDC and registry builds | Cost-competitive mid-market option |
| ImageTrend | ~2–4% | EMS and trauma registries | Category leader in pre-hospital data |
| Medstreaming–M2S | ~2–4% | Vascular and device registries | Strong device-manufacturer relationships |
| OpenText | ~2–4% | Information management, secure exchange | Governance and compliance angle |
| Veradigm | ~2–3% | Specialty registry and RWD networks | Ambulatory network reach |
| Premier Inc. | ~2–3% | Quality collaboratives, benchmarking | Health-system alliance channel |

## Recent News & Developments

## Recent News & Developments

- European Commission (April 2024): Reached political agreement on the European Health Data Space, setting binding secondary-use infrastructure deadlines that anchor a decade of European registry procurement [[2]](https://health.ec.europa.eu).

- Q-Centrix (June 2025): TPG Growth sold its corporate clinical [data management platform](https://www.marketresearchfuture.com/reports/data-management-platform-market-4573) to MRO Corp, which then integrated it with MRO's data exchange network to expand clinical abstraction and registry services to more than 2,000 U.S. hospital partners.

## Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Patient Registry Software Market, software and associated managed services |
| Study Period | 2021–2035 (Historical 2021–2024; Base 2025; Forecast 2026–2035) |
| CAGR | 13.2% (2026–2035) |
| Market Size Checkpoints | USD 2.06 Billion (2025); USD 2.30 Billion (2026); USD 7.01 Billion (2035) |
| Fastest Growing Segments | Pregnancy & maternal-child registries; cloud-deployed SaaS; research institutes and academic medical centres |
| Companies Profiled | 12 vendors including IQVIA, Oracle Health, Optum, Merative, ArborMetrix, Q-Centrix |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: What contract structures do buyers negotiate in the Patient Registry Software Market?**
A: Multi-year subscriptions with abstraction volume tiers dominate. Sophisticated buyers negotiate data-egress rights and exit assistance clauses upfront, because migration cost is the primary lock-in mechanism [11].

**Q: How should a hospital evaluate build versus buy?**
A: Internal builds rarely survive staff turnover or certification refresh cycles. Buy when the registry must submit to an external body; build only for exploratory cohorts with no reporting obligation [11].

**Q: What integration failures most often derail Patient Registry Software Market deployments?**
A: Terminology mapping, not connectivity. Projects stall when local lab codes and problem lists lack clean LOINC and SNOMED mappings, which extends go-live by months [17].

**Q: Do open-source options compete credibly with commercial platforms?**
A: Yes, for research settings. OHDSI-based stacks deliver strong analytics but shift validation, hosting, and regulatory documentation onto the institution, which often erases the licence saving [17].

**Q: What should investors watch in the Patient Registry Software Market?**
A: Net revenue retention above 110% and the share of revenue from managed abstraction. Services attach rate predicts durability better than logo count [14].

**Q: How do device manufacturers use registries differently from providers?**
A: Manufacturers need traceable, audit-ready datasets tied to unique device identifiers for regulatory submission. Providers prioritize clinician usability and benchmarking, so the two groups rarely accept the same configuration [24].

**Q: What emerging use case is underappreciated today?**
A: Registry-linked decentralized trial recruitment. Pre-consented cohorts cut screening timelines substantially, and sponsors are beginning to pay platform fees for that access rather than per-study data licences [16].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/patient-registry-software-market-6917*